Chordate Medical Holding AB Cash Flow Conversion Efficiency
Chordate Medical Holding AB cash flow conversion efficiency. Based on the latest financial reports, Chordate Medical Holding AB (CMH) has a cash flow conversion efficiency ratio of -0.514x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.14 Million ≈ $-768.45K USD) by net assets (Skr13.90 Million ≈ $1.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Chordate Medical Holding AB (2015–2024)
Cash flow conversion efficiency of Chordate Medical Holding AB from 2015 to 2024. This chart illustrates how Chordate Medical Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Chordate Medical Holding AB share price for real-time trading data and today's change.
Chordate Medical Holding AB Cash Flow Conversion Ratio Explained
Chordate Medical Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Chordate Medical Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chordate Medical Holding AB ranked by their cash flow conversion efficiency. Also see how much is Chordate Medical Holding AB worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FAT Brands Inc
NASDAQ:FATBW
|
0.050x |
|
Carisma Therapeutics Inc.
NASDAQ:CARM
|
-2.201x |
|
STRATA Skin Sciences Inc
NASDAQ:SSKN
|
-0.082x |
|
Malvern International
LSE:MLVN
|
-0.476x |
|
Ukrproduct Group
LSE:UKR
|
0.227x |
|
Hamak Gold Ltd
LSE:HAMA
|
0.000x |
|
WICKET GAMING AB
F:7Q4
|
0.015x |
|
Sonder Holdings Inc
NASDAQ:SOND
|
0.040x |
Annual Cash Flow Conversion Efficiency for Chordate Medical Holding AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of Chordate Medical Holding AB from 2015 to 2024. Review Chordate Medical Holding AB (CMH) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr9.20 Million ≈ $989.55K |
Skr-24.41 Million ≈ $-2.63 Million |
-2.654x | -46.89% |
| 2023-12-31 | Skr15.09 Million ≈ $1.62 Million |
Skr-27.26 Million ≈ $-2.93 Million |
-1.807x | +19.89% |
| 2022-12-31 | Skr11.07 Million ≈ $1.19 Million |
Skr-24.98 Million ≈ $-2.69 Million |
-2.256x | -332.08% |
| 2021-12-31 | Skr38.95 Million ≈ $4.19 Million |
Skr-20.34 Million ≈ $-2.19 Million |
-0.522x | +23.19% |
| 2020-12-31 | Skr25.64 Million ≈ $2.76 Million |
Skr-17.43 Million ≈ $-1.88 Million |
-0.680x | +55.95% |
| 2019-12-31 | Skr10.98 Million ≈ $1.18 Million |
Skr-16.95 Million ≈ $-1.82 Million |
-1.543x | +8.48% |
| 2018-12-31 | Skr11.26 Million ≈ $1.21 Million |
Skr-18.99 Million ≈ $-2.04 Million |
-1.686x | -61.95% |
| 2017-12-31 | Skr18.24 Million ≈ $1.96 Million |
Skr-18.99 Million ≈ $-2.04 Million |
-1.041x | -219.15% |
| 2016-12-31 | Skr29.55 Million ≈ $3.18 Million |
Skr-9.64 Million ≈ $-1.04 Million |
-0.326x | +6.19% |
| 2015-12-31 | Skr35.72 Million ≈ $3.84 Million |
Skr-12.42 Million ≈ $-1.34 Million |
-0.348x | -- |
About Chordate Medical Holding AB
Chordate Medical Holding AB (publ), a medical technology company, engages in the development of products and solutions for neurostimulation treatment in Sweden. It offers Ozilia, a neuromodulation and medication-free treatment technology for chronic migraine and chronic rhinitis. The company was founded in 2005 and is based in Kista, Sweden.